Results 11 to 20 of about 9,828 (193)

Flecainide in clinical practice [PDF]

open access: yesCardiology Journal, 2023
Flecainide, similar to encainide and propafenone, is IC class antiarrhythmic, inhibiting Nav1.5 sodium channels in heart muscle cells and modulates cardiac conduction. Despite its over 40-year presence in clinical practice, strong evidence and well-known
Mikołaj Basza   +14 more
doaj   +4 more sources

Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation

open access: yesCase Reports in Cardiology, 2019
Flecainide is a frequently used antiarrhythmic drug, recommended by current guidelines as a first-line treatment option for restoring and maintaining sinus rhythm in patients with atrial fibrillation and no significant structural heart disease.
Erind Gjermeni   +3 more
doaj   +2 more sources

Flecainide associated torsade de pointes: A potential case of reverse use dependence

open access: yesJournal of Research in Medical Sciences, 2013
Flecainide has been known to cause torsades de pointes (TdP) in patients with structural heart disease and its mechanism has been attributed to use-dependency.
Kevin Hayes   +5 more
doaj   +1 more source

Neonatal Near Fatal Flecainide Toxicity

open access: yesSaudi Journal of Emergency Medicine
Background: Flecainide is an anti-arrhythmic medication with a narrow therapeutic index and a high mortality rate, when overdosed. Few cases of flecainide toxicity in neonates and children due to medication error have been reported in the literature.
Fatma Mohammed Abdullah Al Balushi   +5 more
doaj   +2 more sources

Flecainide for conversion and maintenance of sinus rhythm after mitral valve replacement in rheumatic atrial fibrillationWhat is Already Known?What this Study Adds

open access: yesIndian Heart Journal, 2023
Background: Despite successful mitral valve replacement (MVR), many patients remain in AF. Flecainide can be useful in these patients but has not been used because of underlying structural heart disease.
Umesh Tripathi   +10 more
doaj   +1 more source

Flecainide in ventricular arrhythmias. from old myths to new perspectives [PDF]

open access: yes, 2021
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF).
Michele Magnocavallo   +21 more
core   +2 more sources

Flecainide intoxication in pediatric patients with supraventricular tachycardia

open access: yesAnnals of Pediatric Cardiology, 2020
Flecainide is a class IC antiarrhythmic indicated for ventricular and supraventricular arrhythmias in pediatric patients without structural heart disease.
Guiem Vaquer   +5 more
doaj   +1 more source

The Effects of Flecainide Acetate on Inflammatory-Immune Response in Lipopolysaccharide-Stimulated Neutrophils and on Mortality in Septic Rats [PDF]

open access: yesAcute and Critical Care, 2018
Background Flecainide acetate is a drug used primarily for cardiac arrhythmia. Some studies also imply that flecainide acetate has the potential to regulate inflammatory-immune responses; however, its mechanism of action is contended.
Shi Young Chung   +5 more
doaj   +1 more source

Exercise Testing With Flecainide Demonstrates Provocable Brugada Syndrome

open access: yesCJC Open, 2021
A young man with baseline early repolarization was initiated on flecainide and diltiazem for symptomatic atrial arrhythmias. A treadmill stress test induced a type 1 Brugada electrocardiogram pattern at higher heart rates.
Sina Safabakhsh, BSc,   +2 more
doaj   +1 more source

The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia

open access: yesFrontiers in Physiology, 2022
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe yet rare inherited arrhythmia disorder. The cornerstone of CPVT medical therapy is the use of β-blockers; 30% of patients with CPVT do not respond well to optimal β-blocker ...
Yukun Li   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy